Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

M.C. Dubinsky, P.M. Irving, X.Y. Li, S. Howaldt, J. Pokrotnieks, K.A. Krueger, J. Laskowski, T. Lissoos, J. Milata, N. Morris, V. Arora, C. Milch, B.E. Sands

Research output: Contribution to journalMeeting Abstractpeer-review

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this